Thrombolex Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant from the National Heart, Lung and Blood Institute (NHLBI) section of the National Institutes of Health to fund the company's pivotal RESCUE trial under an investigational device exemption.
|